Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
[Research progress of the selective sphingosine-1-phosphate receptor 1 agonists].
Compressive myelopathy: magnetic resonance imaging findings simulating idiopathic acute transverse myelopathy.
[Neuromyelitis optica.]
Substance Name: Riluzole
Immune-related GTPase Irgm1 exacerbates experimental auto-immune encephalomyelitis by promoting the disruption of blood-brain barrier and blood-cerebrospinal fluid barrier.
Transplantation of Placenta-Derived Mesenchymal Stem Cells in the EAE Mouse Model of MS.
The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?
Disc swelling and mild initial visual acuity loss predict a better short-term visual acuity outcome in bilateral acute optic neuritis.
Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment.
Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis.
Biologically plausible and evidence-based risk intervals in immunization safety research.
Balance exercise program reduced falls in people with multiple sclerosis - a single group pretest posttest trial.
Development of nucleic acid drugs for neurological disorders.
Presumptive Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis after Natalizumab Therapy.
Selective depression of low-release probability excitatory synapses by sodium channel blockers.
A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: relevance to multiple sclerosis.
A cluster randomised controlled trial on the efficacy of client-centred occupational therapy in multiple sclerosis: good process, poor outcome.
Enhanced myelination in autoimmunity and in normal development induced by glatiramer acetate.
NMO spectrum presenting as partial myelitis.
Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease.
[Neuromyelitis optica in the elderly: An unusual demyelinating disease.]
Association of a deficit of arousal with fatigue in multiple sclerosis: Effect of modafinil.
The Alice in Wonderland syndrome: an unusual in acute disseminated encephalomyelitis.
Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis.
Pages
« first
‹ previous
…
167
168
169
170
171
172
173
174
175
…
next ›
last »